shutterstock_1826152037_lev_radin
Lev Radin / Shutterstock.com
16 January 2024PharmaLiz Hockley

Regeneron sues Amgen over biosimilar version of blockbuster eye drug

US biotech has launched multiple suits over alleged infringement of Eylea patents | Regeneron asks US court to block Amgen’s biosimilar before potential approval.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
11 August 2026   A litigation campaign against generic drugmakers, including Sandoz, Hikma, and Amenal, raise the stakes in the fight over two of the world’s most lucrative weight loss and diabetes treatments.
Pharma
10 August 2026   Takanori Abe of Abe & Partners brings the perspective of a lawyer with first-hand experience in the German courtrooms to Pharmaceutical, Biological and Chemical Patents, a valuable resource on case law.
Pharma
6 August 2026   A Netherlands court ruling marks the latest win as Novo Nordisk ramps up efforts to protect semaglutide from unapproved products, copycats and an increasingly competitive market.